Trials / Active Not Recruiting
Active Not RecruitingNCT05565378
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 351 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will monitor the safety of novel immunotherapy combinations in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] \>= 50%), previously untreated, unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC). Drug name mentioned as Belrestotug, GSK4428859A, and EOS884448 are all interchangeable for the same compound. In the rest of the document, the drug will be referred to as Belrestotug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab will be administered. |
| DRUG | Dostarlimab | Dostarlimab will be administered |
| DRUG | Belrestotug | Belrestotug will be administered. |
| DRUG | Nelistotug | Nelistotug will be administered. |
Timeline
- Start date
- 2022-10-14
- Primary completion
- 2027-02-26
- Completion
- 2027-02-26
- First posted
- 2022-10-04
- Last updated
- 2026-01-08
Locations
99 sites across 22 countries: United States, Argentina, Belgium, Brazil, Finland, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Netherlands, Poland, Portugal, South Africa, South Korea, Spain, Thailand, Turkey (Türkiye), United Arab Emirates, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05565378. Inclusion in this directory is not an endorsement.